Amanta Healthcare LtdQ1 FY27
Amanta Healthcare Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹195P/E: 39.6Market Cap: ₹607 CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →SteriPort Line 3 expected to contribute around INR120 crores annualized revenue, fully realized within 12 months post-commissioning (from August 2026).
- →SteriPort projected to generate roughly INR70 crores in top line during the 7 months remaining in FY27 and about INR425 crores revenue at peak utilization in FY28 including SVP.
- →SVP facility to commence operations by March 2027, expected to drive growth in export-focused products like inhalation, ophthalmics, and preservative-free unit doses.
- →SVP export revenues anticipated to comprise 60%-70% from advanced regulated markets (UK, Ireland, EU, Australia, Canada).
- →Future growth drivers for FY27-FY29: inhalation products, ophthalmics, diluents in advanced markets.
- →Focus on expanding sterile dosage forms, including exploring other packaging materials and drug delivery mechanisms beyond plastic.
- →Capacity expansions and formulation development pipeline (20 products) expected to support sustained growth over next 2-3 years.
- →Interest expense expected to reduce by FY28 indicating easing capex cycle.
Margin guidance
Category 3- →SteriPort Line 3 commissioning expected by August 2026, with annualized peak revenue of INR110-120 crores achievable within 12 months of commissioning.
- →SVP facility to commence operations by March 2027, expanding presence in high-margin export markets (inhalation solutions, ophthalmics, preservative-free unit doses).
- →Combined full capacity (SteriPort + SVP + existing) expected to generate peak revenue of around INR425 crores in FY28 with EBITDA around INR116 crores.
- →Incremental ROCE on SteriPort Line 3 estimated at 16%-17%; SVP ROCE expected around 14%-15%.
- →Operating leverage to improve with scaling, supported by captive solar power reducing power costs significantly (INR9 crores cost savings).
- →EBITDA margins expected to remain stable around 25%-26% for FY27 and FY28.
- →Interest expense expected to reduce after peak capex cycle; INR18-19 crores annualized interest expected in FY28.
- →Growth drivers include new product pipeline with ~20 products under development, including inhalation and ophthalmics targeting advanced markets.
3 more insights locked — sign up free to unlock
Fundraise plans
- →No explicit mention of any new fundraising through debt or equity in the provided transcript.
- →Existing debt is being managed and expected to reduce annually by INR30-35 crores.
- →Additional debt was taken for the solar captive power project but it is a strategic cost-saving move.
- →Interest expenses are expected to reduce going forward as debt decreases.
- →Current and near-term capex (SteriPort Line 3, SVP, solar) is mostly funded, with INR80 crores spent on SteriPort Line 3 and part of INR30 crores on SVP already spent.
- →No discussion of fresh equity or debt issuance planned beyond current operational and capex financing.
Order book
The transcript provided does not explicitly mention the current or expected order book or pending orders for Amanta Healthcare Limited. However, some relevant insights include:
- There is strong demand for SteriPort products, leading to an expansion in capacity from 6.6 crore to approximately 12 crore bottles per year.
- SteriPort Line 3 commissioning is expected around August 24-25, 2026, with annualized revenue expected at INR 120 crores.
- SVP facility is expected to be operational by March 2027, targeting advanced regulated markets with 60%-70% of SVP revenue expected from these markets.
- The company is leveraging increasing demand with near-full utilization of existing capacities.
- No direct comments on the size or value of the order book or pending orders were disclosed in the available transcript.
Capex plans
Yes- →SteriPort Line 3: Total capex of INR 90 crores; approx. INR 80 crores spent so far; commissioning expected by August 24-25, 2026.
- →SVP Expansion: Total capex of INR 30 crores; about INR 7 crores spent so far; expected to be operational by March 2027.
- →No immediate further capex planned for SteriPort beyond Line 3, despite demand-supply mismatch.
- →Future exploration of other drug delivery mechanisms and packaging materials (e.g., glass) beyond current plastic packaging, with clarity expected by December 2026 or January 2027.
- →Investment in formulation development team and new center under construction, intending 8-10 scientists and 3-4 regulatory affairs personnel for advanced markets.
- →Solar power captive project capex contributing to slight interest expense increase; reduces monthly operational costs by approx. INR 75 lakh.
- →Post-2027, focus will be on activity-centric investments to support existing capacity rather than large capex.
How does Amanta Healthcare Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Amanta Healthcare Ltd
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Amanta Healthcare Ltd rank in Pharmaceuticals & Biotechnology?
Compare Amanta Healthcare Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.